Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
Chiari R, Metro G, Iacono D, Bellezza G, Rebonato A, Dubini A, Sperduti I, Bennati C, Paglialunga L, Burgio MA, Baglivo S, Giusti R, Minotti V, Delmonte A, Crinò L. Chiari R, et al. Lung Cancer. 2015 Nov;90(2):255-60. doi: 10.1016/j.lungcan.2015.09.009. Epub 2015 Sep 14. Lung Cancer. 2015. PMID: 26395848
c-Met targeting in advanced gastric cancer: An open challenge.
Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A. Marano L, et al. Among authors: chiari r. Cancer Lett. 2015 Aug 28;365(1):30-6. doi: 10.1016/j.canlet.2015.05.028. Epub 2015 Jun 3. Cancer Lett. 2015. PMID: 26049023 Review.
Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients.
Metro G, Giannarelli D, Sidoni A, Chiari R, Bellezza G. Metro G, et al. Among authors: chiari r. Int J Biol Markers. 2018 Apr 1:1724600818754763. doi: 10.1177/1724600818754763. Online ahead of print. Int J Biol Markers. 2018. PMID: 29683065 Free article. No abstract available.
Primary and metastatic brain tumors.
Franceschi E, Scopece L, Gori S, Chiari R, Crino L. Franceschi E, et al. Among authors: chiari r. Forum (Genova). 2006;14(1):E2. Forum (Genova). 2006. PMID: 16873085
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. Ludovini V, et al. Among authors: chiari r. J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b. J Thorac Oncol. 2011. PMID: 21258250 Free article.
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer MJ, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò L. Metro G, et al. Among authors: chiari r. Cancer Chemother Pharmacol. 2011 Dec;68(6):1405-12. doi: 10.1007/s00280-011-1632-x. Epub 2011 Apr 6. Cancer Chemother Pharmacol. 2011. PMID: 21468755
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L. Ludovini V, et al. Among authors: chiari r. J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f. J Thorac Oncol. 2011. PMID: 22052224 Free article.
209 results